You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD22 CAR-T

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-hodgkin's Lymphoma Trial in Langfang (CD19+22 CAR-T cells)

Recruiting
  • Non-hodgkin's Lymphoma
  • CD19+22 CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jan 11, 2022

B-Cell Acute Lymphoblastic Leukemia, Adult Trial in Hangzhou (CAR-T cells targeting CD19 and CD22)

Recruiting
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • CAR-T cells targeting CD19 and CD22
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Mar 5, 2021

Lymphoma, B-Cell Trial in Xi'an (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Terminated
  • Lymphoma, B-Cell
  • Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Oct 28, 2021

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)

Unknown status
  • Leukemia
  • Lymphoma
  • Anti-CD22-CAR-transduced T cells
  • Beijing, Beijing, China
    Fengtai District
Feb 6, 2021

Lymphoma, B-Cell Trial in Taiyuan (CD19-CD22 CAR-T cells)

Recruiting
  • Lymphoma, B-Cell
  • CD19-CD22 CAR-T cells
  • Taiyuan, Shanxi, China
    Hematology Department of ShanXi Cancer Hospital
Jan 17, 2021

B-Cell Acute Lymphoblastic Leukemia, Adult Trial in Hangzhou (CAR-T cells targeting CD19 and CD22)

Recruiting
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • CAR-T cells targeting CD19 and CD22
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Feb 4, 2021

Acute Lymphocytic Leukemia, B-Cell Trial in Taiyuan (CD19-CD22 CAR-T cells)

Recruiting
  • Acute Lymphocytic Leukemia， B-Cell
  • CD19-CD22 CAR-T cells
  • Taiyuan, Shanxi, China
    Hematology Department of ShanXi Cancer Hospital
Jan 17, 2021

B-ALL Trial in Kunming (CD19 and CD22 targeted prime CAR-T cells)

Recruiting
  • B-ALL
  • CD19 and CD22 targeted prime CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
Jul 30, 2021

B Cell Lymphoma Trial in Kunming (CD19 and CD22 targeted prime CAR- T cells)

Recruiting
  • B Cell Lymphoma
  • CD19 and CD22 targeted prime CAR- T cells
  • Kunming, Yunnnan, China
    920th Hospital of Joint Logistics Support Force
Jul 30, 2021

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Oct 19, 2022

Refractory Indolent Adult Non-Hodgkin Lymphoma Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)

Recruiting
  • Refractory Indolent Adult Non-Hodgkin Lymphoma
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

B-ALL Trial in Heibei, Beijing (CD22 CAR-T)

Unknown status
  • B-ALL
  • CD22 CAR-T
  • Heibei, Sanhe, China
  • +1 more
Sep 4, 2020

Adult B Acute Lymphoblastic Leukemia Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)

Recruiting
  • Adult B Acute Lymphoblastic Leukemia
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

B-cell Malignancy Trial in Xuzhou (ThisCART22 cells)

Recruiting
  • B-cell Malignancy
  • ThisCART22 cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Nov 9, 2021

Refractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia Trial in Xi'an (Dual Specificity CD19 and CD22

Withdrawn
  • Refractory B Acute Lymphoblastic Leukemia
  • Relapse B Acute Lymphoblastic Leukemia
  • Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Nov 3, 2020

Multiple Myeloma Trial in Taiyuan (CD19-CD22 CAR-T cells)

Recruiting
  • Multiple Myeloma
  • CD19-CD22 CAR-T cells
  • Taiyuan, Shanxi, China
    Hematology Department of ShanXi Cancer Hospital
Jan 17, 2021

B-Cell Leukemia, B-Cell Lymphoma Trial in Guangzhou (4SCAR19/22 T cells, Interleukin-2)

Suspended
  • B-Cell Leukemia
  • B-Cell Lymphoma
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Aug 9, 2021

Leukemia, B-cell, Lymphoma, B-Cell Trial in Chongqing (CD19 and CD22 targeted CAR-T cells)

Recruiting
  • Leukemia, B-cell
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 1, 2021

Leukemia, B-Cell Trial in Houston (Autologous TriCAR T-cells and lymphodepletion chemo)

Not yet recruiting
  • Leukemia, B-Cell
  • Autologous TriCAR T-cells and lymphodepletion chemotherapy
  • Houston, Texas
  • +1 more
Nov 3, 2021

Childhood Acute Lymphoblastic Leukemia Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD 19+22)

Recruiting
  • Childhood Acute Lymphoblastic Leukemia
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

Recruiting
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Variant
  • CD22CART cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood,

Recruiting
  • Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood
  • +2 more
  • CAR-T19/CAR-T22
  • Changsha, Hunan, China
    Xiangya Hospital Central South University
Feb 3, 2021

Dual-target CAR-T Cells, B ALL, Relapse Trial in Shenzhen (Dual target CAR-T cell therapy)

Unknown status
  • Dual-target CAR-T Cells
  • +3 more
  • Dual target CAR-T cell therapy
  • Shenzhen, Guangdong, China
    Shenzhen University General hospital
Jan 23, 2021

T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)

Recruiting
  • T-Cell Acute Lymphocytic Leukemia
  • CD7 CAR-T
  • Langfang, Hebei, China
    Hebei Yanda Hospital
Jun 26, 2023